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Abstract
The cyclin kinase inhibitor p27kip1 acts as a potent tumor supressor protein in a variety of human
cancers. Its expression levels correlate closely with the overall prognosis of the affected patient and
often predict the outcome to different treatment modalities. In contrast to other tumor
suppressor proteins p27 expression levels in tumor cells are frequently regulated by ubiquitin
dependent proteolysis. Re-expression of p27 in cancer cells therefore does not require gene
therapy but can be achieved by interfering with the protein turnover machinery. In this review we
will summarize experimental results which highlight the potential use of p27 as a target for
oncological therapies.
Review
Introduction
Oncology, the science which aims to understand the
development, diagnosis, treatment, and prevention of
human cancers, has undergone major changes in recent
years. The introduction of targeted drugs which interfere
with signal transduction cascades to block tumor cell pro-
liferation is only the beginning of a fundamental change
in the way cancer is treated. These significant advances in
clinical oncology were made possible through the
detailed analysis of the molecular origins of human can-
cers [1]. From these studies we learned that most human
cancers undergo genetic changes to escape external con-
trol mechanisms which normally regulate cell division.
Cell divison in turn is regulated by a highly conserved
group of proteins which together constitute the basic cell
divison machinery that controls the cell cycle [2]. Changes
in the expression or activity levels of these proteins are
almost always detected in human cancer cells and in
many cases are targets of genetic alterations which lead to
cancer formation. The cyclin kinase inhibitor p27kip1 plays
a central role in the suppression of tumorigenesis in a vari-
ety of human cancers [3]. The best understood function of
this protein is the inhibition of the activity of cyclin E or
A containing cdk2 (cyclin dependent kinase 2) complexes.
This function enables p27 to regulate the progression of a
cell from a quiescent state into the G1 phase and from the
G1 phase into S-phase. Several external signals either
induce an increase (TGFβ, serum starvation, contact inhi-
bition and others) or a decrease (serum stimulation, estro-
gen, Il2, PDGF and others) in p27 cellular levels thereby
allowing p27 to become a central mediator of mitogenic
and anti-mitogenic pathways [4]. p27 expression levels
are regulated by transcriptional, translational and post-
translational mechanisms. Of particular importance for
the development of human cancers is the ubiquitin
dependent degradation of p27 by the proteasome. This
pathway is controlled by phosphorylation of p27 at a con-
served Threonine (T187) by cyclin E/cdk2 complexes and
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by the expression of the F-Box protein skp2 which facili-
tates polyubiquitylation of p27 by the SCF complex [5-7].
In addition to being expressed at insufficient levels p27
can also be functionally inactivated by being mislocalized
to the cytoplasm or through phosphorylation events
which prevent binding to its critical cellular targets i.e cyc-
lin E and A/cdk2 complexes. The discovery that phospho-
rylation by AKT and SRC kinases at either T157 (AKT) or
Tyrosine 74, 88 (SRC) induces cellular mislocalization or
functional inactivation and degradation has broadened
the spectrum of oncogenic mechanisms which disable
p27, i.e., as a tumor suppressor protein [8,9].
The fact that p27 expression levels and its cellular func-
tions are under the control of well characterized post-
translational mechanisms makes it an interesting target
for pharmaceutical interventions. Such therapies would
aim at the stabilization of p27 in tumor tissues by interfer-
ing with the enzymatic machinery that controls p27
destruction. Given the enormous efforts and costs con-
nected to the development of such new drugs proper
selection of potential drug targets is of major importance.
In this review we will ask if the cyclin kinase inhibitor
p27kip1  could be a valuable target for pharmaceutical
intervention.
Frequency of deregulation of p27 in human 
cancer
An overwhelming number of studies have shown that
reduced expression levels of p27 in primary cancer tissue
correlates with reduced overall and progression free sur-
vival as well as poor response to chemotherapies or tar-
geted treatments. Inverse correlations between patient
prognosis and p27 levels were shown in breast, prostate,
bladder, lung, glia, liver, larynx, ovary, stomach, and other
tissues. This concept has been summarized extensively in
several excellent reviews [3,4,10]. While certain tumor
types for example AML and ALL show larger deletions of
the genomic area in which p27 is located no somatic
mutations of the remaining allele have been identified
[11]. In general and in strong contrast to other tumor sup-
pressor proteins somatic mutations in the p27 locus are
very rare in human cancers. A noteable exception from
this rule is the recent finding that a rat strain which dis-
plays a MEN (multiple endocrine neoplasia) like pheno-
type syndrome (MENX) shows a mutation in the rat p27
locus which leads to a reduction of p27 levels in different
rat tissues. Interestingly the authors also identify a human
patient with a MEN like syndrome with a germline muta-
tion in the p27 locus. Nevertheless this study is a rare
example of a genetic alteration of the p27 locus [12].
The majority of studies in which the expression levels of
p27 were measured in human tumor specimens conclude
that the reduction of p27 levels is caused by an increase in
protein degradation. Since the discovery of skp2 as the
essential F-Box protein that controls p27 stability several
examples of an inverse correlation between skp2 and p27
expression in different tumors have been published [13].
Some studies even showed that tissues from tumors which
express low levels of p27, i.e, colon carcinoma, mantle cell
lymphoma, small cell lung cancer and others, also dis-
played an increase in p27 degradatory activity [14,15].
Validation of p27 contribution to tumorigenesis 
in model systems
This correlative data from human cancer samples in which
the number of p27 expressing cells was determined by
immune staining is now supported by a great number of
mouse studies. Loss of p27 in the mouse confers only a
relatively mild tumor phenotype leading to the develop-
ment of pituitary adenomas and prostate hyperplasia with
increasing age [16-18]. However Fero and co-workers
showed that p27 knockout mice have a greatly increased
susceptibility to the development of cancers after treat-
ment with chemical carcinogens or irradiation [19]. Their
study also showed that loss of just one p27 allele is suffi-
cient to increase the overall number of tumors that arise
and shortens the overall survival of the affected mouse.
These initial studies were followed by a great number of
experiments in which the contribution of p27 loss to the
development of various cancer types in mouse models has
been evaluated. For example, loss of p27 on a hetero-
zygous PTEN background leads to a dramatic increase in
the incidence of precursor lesions which progress to carci-
noma in situ or even invasive carcinomas of the prostate,
while PTEN mice with intact p27 expression develop
fewer precursor lesions which do not progress to more
malignant states [20]. Similar results were found in mod-
els for pituitary cancer, lymphoma, testicular cancer and
others [21,22]. In colon cancer models loss of p27 coop-
erated with mutation in the APC (min) gene but showed
no cooperativity with mutations in the Smad3 gene which
is part of the TGFβ pathway [23]. In general these studies
highlight the fact that a reduction of p27 levels promotes
tumor development fueled by most but not all oncogenic
events.
Interference with p27 activity reverses or blocks 
the malignant phenotype
The observations made in mouse models in combination
with the facts that p27 is primarily (but not exclusively)
regulated by post-translational mechanisms has spurred
interest in developing methods which target the enzy-
matic machinery that regulates the degradation of p27.
Studies in which p27 was over-expressed through differ-
ent types of transfection or infection techniques had
shown that re-expression of p27 in tumor cells (brain,
lung, breast) often induces apoptosis [24,25]. The mecha-Cell Division 2007, 2:13 http://www.celldiv.com/content/2/1/13
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nism by which p27 overexpression in tumor cells induces
apoptosis is largely unknown. Overexpression of p27 in
primary non-transformed cells however usually arrests the
cell in G0/G1 thereby providing some degree of specificity
to a "p27 therapy". Based on the detailed analysis of p27
degradation by the skp2 dependent SCF complex it seems
now possible to interfere with p27 degradation in a much
more specific way. One way is the direct interference with
skp2 expression either by siRNA or blocking antibodies.
Both treatments were shown to reduce the ability of skp2
to degrade p27 thereby blocking cell proliferation of lung
cancer, oral cancer and melanoma cells. [26-28]
By using a mouse model in which expression of a degra-
dation resistant version of p27 (p27T187A) led to a reduc-
tion in the number of adenomatous polyps which
progressed to invasive intestinal carcinomas, we recently
demonstrated that p27 stabilizing treatments might be of
clinical value. This study showed that in contrast to
wildtype p27, p27T187A expression was maintained
throughout the course of intestinal carcinogenesis and
correlated with the delayed progression of the intestial
tumors in the p27T187A mouse. Because the expression
of the degradation resistant version of p27 is under the
control of the genomic p27 promoter the cellular levels of
the T187A form that were reached in this study were exclu-
sively caused by a reduction in the rate of protein turno-
ver. This study therefore showed that treatments aimed at
reducing p27 degradation might be of therapeutic value in
patients with colon cancer. Interestingly the stabilization
of p27 did not lead to a reduction in the proliferation rates
of the tumor tissue but instead affected the de-differentia-
tion of the pre-cancerous adenoma into malignant carci-
nomas [29]. Similar observations have previously been
made in human colon carcinomas in which p27 express-
ing tumors showed a more differentiated phenotype than
low expressing cancers [30]. These studies point to the
interesting question as to how p27 expression might inter-
fere with cellular differentiation programs. Indeed, studies
in colon epithelial cells showed that while the overexpres-
sion of both p16 and p27 led to a reduction in cellular
proliferation rates the expression of only p27 induced dif-
ferentiation associated changes in morphology as well
[31]. Strong evidence for a role of p27 in differentiation
programs comes from studies of xenopus neurogenesis.
Here overexpression of a non cdk inhibitory mutant of
p27xic1, the xenopus homologue of p27kip1, induces differ-
entiation of immature neurons [32]. This observation was
recently validated in a knock-in mouse model in which
p27c-k- (a mutant form of p27 which cannot bind cyclin or
cdk) promoted normal brain development while p27 KO
mice show specific defects in this process [33]. In analogy
to the results in xenopus neural development p27 seems
to stabilize the protein neurogenin which is essential for
neural differentiation by preventing its degradation. It is
therefore conceivable that drugs which prevent p27 degra-
dation will in addition to causing apoptosis affect tumor
cell de-differentiation.
Potential risks of p27 stabilizing therapies- the 
dark side of p27
Based on our knowledge regarding the function and regu-
lation of p27 in normal and tumor cells it appears that a
p27 stabilizing therapy could be clinically beneficial.
However the fact that the p27 gene is only very rarely
mutated in human cancers also points to potential risks
associated with such an approach. Intuitively one would
argue that if a tumor cell does not mutate a tumor sup-
pressor gene this could indicate that the protein might
have a tumor promoting function at least in the early
stages of tumor initiation. If such functions would exist
stabilization of p27 in tumor cells might actually not
inhibit tumorigenesis but promote it. In fact several
tumor promoting functions of p27 are conceivable.
First, p27 as well as p21 can function as assembly factors
for cyclin D/cdk4 complexes thereby promoting Rb phos-
phorylation and cell cycle progression [34]. It is however
difficult to experimentally determine to which extent the
assembly function of p27 contributes to tumorigenesis.
Loss of p27 should impair cyclin D/cdk4 activation (at
least when p21 is deleted at the same time), however
some p27 KO cells and tissues show increased levels of
cdk2 dependent kinase activity thereby essentially circum-
venting the need for cyclin D kinase activation. Neverthe-
less in an ErbB2 dependent mouse breast cancer model
Muraoka and co-workers showed that while loss of one
p27 allele accelerated breast cancer development loss of
both alleles decreased cyclin D dependent kinase activity
which correlated with an increased tumor latency [35]. A
similar effect was shown in mice in which the combined
loss of the homeobox gene Nkx3.1 and p27kip1 on a PTEN
heterozygous background showed a reduced tumor inci-
dence as compared to p27 heterozygous, Nkx3.1-/-, PTEN
+/- mice [36]. In this model heterozygous p27 mice
showed a significantly higher expression of cylin D than
p27 knockout mice. Also heterozygous p27 knockout
mice are more prone to urtehane induced lung tumori-
genesis then p27 knockout mice [37]. These studies indi-
cate that in different tumor models some p27 expression
is necessary to allow tumor-initiation in breast, lung and
prostate tissue. A p27 stabilizing drug would therefore
need to induce p27 expression close to wildtype levels to
be of clinical benefit. Otherwise re-expression of p27 in
tumors could facilitate the expression and activation of
cyclin D kinase activity thereby promoting tumor progres-
sion.
Studying phosphorylation dependent regulation of p27
we recently identified Threonine 198 in p27 as a phos-Cell Division 2007, 2:13 http://www.celldiv.com/content/2/1/13
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phorylation site which controls binding of p27 to cyclin
D/cdk4 complexes. Phosphorylation at T198 is required
to form cyclin D/cdk4 complexes which in turn phospho-
rylate Rb to allow the activation of an E2F dependent tran-
scriptional program. Interestingly AKT kinase has been
shown to phosphorylate p27 at T198 while being itself an
E2F target gene. Expression of p27 in early G1 might
therefore help to induce AKT expression which in turn
promotes cyclin D/cdk4 assembly through phosphoryla-
tion of p27 at T198. In this scenario p27 would be part of
a positive feedback loop which promotes progression
through this early part of the G1 phase. Expression of a
non-phosphorylatable version of p27 (p27T198A) inter-
feres with timely Rb phosphorylation thereby blocking
cell cycle progression [38]. The cellular response to p27
overexpression might therefore be regulated by the activ-
ity of other signalling cascades i.e. AKT activity which will
also impinge on the ability of a p27 stabilizing drug to
block tumor cell proliferation.
In addition to its function in cell cycle control other non-
cdk inhibitory functions of p27 have been identified in
recent years. These functions would also be affected by
treatments which lead to an increase in the cellular levels
of p27. Particularly interesting was the finding that p27 is
involved in the regulation of cell migration. In an impor-
tant paper, Besson and Roberts showed that p27 knockout
cells have a significantly reduced ability to migrate due to
a defect in down regulating RhoA activity [39]. The ability
of p27 to regulate RhoA was indeed independent of its
function as a cyclin kinase inhibitor as a mutant version
of p27c-k- also induced migration in p27 knockout cells.
Essentially and as discussed by the authors this observa-
tion suggests that loss of p27 should impair the ability of
a tumor cell to migrate thereby reducing its capacity to
invade the surrounding tissue or metastasize to other
organs. Recent data suggests that some cancers metasta-
size relatively early in the course of their development;
breast cancer is a prominent example of such an early
metastasizing tumor [40]. However breast cancers also
show a very strong correlation between low p27 levels and
reduced prognosis of the affected patients [41]. Maybe
early metastasis formation is promoted in tumor cells
which still express sufficient levels of p27 to suppress
RhoA activity while the degradation of p27 allows the
rapid proliferation of the daughter cells.
Breast cancers also show an additional feature of p27 inac-
tivation namely the exclusion of p27 from the nucleus.
Work by several laboratories convincingly showed that
phosphorylation of p27 by AKT at T157 and also at T198
is required for nucleo-cytoplasmic transport [42-46].
Cytoplasmic expression of p27 in breast cancer cells and
in Barretts associated adenocarcinoma of the esophagus
correlated with a reduced prognosis, indicating that cyto-
plasmic localization of p27 inactivates the tumor suppres-
sor function of the protein [47]. However these
observations do not exclude the possibility that cytoplas-
mic p27 gains additional functions which might even
favour tumor cell proliferation or survival. A recent study
by Wu and Arteaga addressed this problem experimen-
tally by expressing a mutant form of p27 which cannot
localize to the nucleus in MCF7 breast cancer cells. In cells
in which p27 is normally cytoplasmic loss of p27 destabi-
lized AKT while overexpression lead to an increase in AKT
stability and tumor cell survival. The authors then
extended their study to a series of human breast cancer
specimens in which they showed that cytosolic p27
expression levels correlated with the expression levels of
AKT and to a lesser degree the activiation of AKT as meas-
ured by phospho-AKT staining [48]. This data therefore
points to an anti-apoptotic function of cytosolic p27
mediated at least in part through the activation of AKT
kinase. Further support for an anti-apoptotic function of
p27 was also shown in leukemic cells in which p27 can
confer resistance to apoptosis after treatment with chem-
otherapeutic drugs. These experiments suggested that p27
itself can be cleaved by caspases to yield smaller fragments
which protected the cell against apoptosis while non-
cleavable forms of p27 do not [49]. Moreover p27 con-
ferred chemotherapy resistance to tumor cells grown as
spheroids most likely through the induction of a G1 arrest
while reduction of p27 expression allowed efficient killing
of the respective cells. p27 stabilization could therefore
affect the efficiency of chemotherapeutic drugs by limiting
the number of cycling cells and  reduce the sensitivity
against apoptosis in certain cell types [50].
As discussed before, the skp2/p27 interaction represents
an attractive target for pharmacological intervention.
However loss of skp2 leads to severe alterations in cell
physiology, specifically centrosome overamplification
and DNA re-replication cycles which lead to largely
increased chromosome numbers in skp2 knockout hepa-
tocytes and other cell types [51,52]. It is unclear whether
the acute loss of skp2 function would induce the same
changes at the organismal level or would primarily
increase the expression of p27. Tumor studies in skp2
knockout mice and specifically in skp2 heterozygous mice
could shed light on these questions.
Conclusion
The strong correlation between p27 levels and patient sur-
vival in a variety of human malignancies underscores the
important contribution of p27 to human carcinogenesis.
These observations were experimentally proven in numer-
ous mouse studies in which loss or reduction of p27
expression synergized with different oncogenes. Given the
importance of ubiquitin dependent degradation mecha-
nisms for the turnover of p27, therapies aimed at the sta-Cell Division 2007, 2:13 http://www.celldiv.com/content/2/1/13
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bilization of p27 could therefore be of clinical value.
Nevertheless recent studies revealed additional functions
of p27 specifically the regulation of cell migration and the
interaction with signal transduction cascades which point
to potential risks connected with the stabilization of p27.
Through use of the existing mouse models which express
mutant forms of p27 it should however be possible to
identify those types of cancer in which p27 stabilization is
clinically beneficial. One such example is intestinal cancer
in which the results obtained by studying human colon
carcinoma samples match the observations made in
mouse lines which express more stable forms of p27,
namely that preventing p27 turnover represents an inter-
esting new target for molecular cancer therapies.
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